Market Report Source

Overview

The number of patients eligible for cardiovascular therapies is increasing quickly, and, as in the developed pharmaceutical markets, is primarily driven by increases in prevalence in diabetes and obesity, trends that do not appear likely to diminish over the period 2004-10. The number of cardiovascular disease sufferers is increasing as a result of the increasing prevalence of cardiovascular risk factors, although rising spending on pharmaceuticals, particularly in dyslipidemia and thrombosis, is improving the primary incidence and the mortality associated with acute thrombotic events. Dyslipidemia is the most common cardiovascular risk factor with an estimated prevalence rate of 34.8% in 2004 across the twelve Eastern European markets, or 99m individuals. Hypertension is the second most common cardiovascular risk factor in the twelve Eastern European markets. In 2004, the prevalence of hypertension in Eastern Europe was estimated at 16.4% or 47m individuals. The prevalence of diabetes is forecast to become increasingly significant in the epidemiology of cardiovascular disease. The prevalence rate of diabetes in the twelve Eastern European markets was estimated at 9.3% during 2004, but is forecast to increase to 9.7% in 2010. 38m cases of cardiovascular disease were estimated to be affect the regional population in 2004, with angina and peripheral artery disease estimated to be the most prevalent diseases with incidences of 11m and 19m cases respectively in 2004.

Table of Contents

Table of Contents

The Eastern European Cardiovascular Market Outlook

to

Executive Summary

Patient potential

Regional healthcare and licensing

Regional market analysis

Key players in the Eastern European cardiovascular market

Chapter 1 Patient potential

Summary

Introduction

Disease description

Defining patient potential

Limitations of cardiovascular epidemiology data

Cardiovascular risk factors

Hypertension

Prevalence

Factors driving prevalence

Forecast prevalence

Dyslipidemia

Prevalence

Factors driving prevalence

Forecast prevalence

Diabetes

Prevalence

Forecast prevalence

Cardiovascular disease

Prevalence

Acute thrombotic events

Acute coronary syndromes

Venous thromboembolism

Stroke

iv

Chapter 2 Regional healthcare and licensing trends

Summary

Introduction

Regional healthcare expenditure

Healthcare financing

The external environment

Licensing analysis

Chapter 3 Regional market analysis

Summary

Introduction

Market breakdown by therapeutic area

Leading products

Market breakdown by country

Anti-hypertensives

Introduction

Analysis of the top 10 anti-hypertensives

Hypertension class sales by country, 2004

Market analysis by drug class

ACE inhibitors

Calcium channel blockers

Beta blockers

Other major classes of drugs

Anti-hypertensives sales forecasts

Dyslipidemia

Introduction

Analysis of the top 10 anti-dyslipidemics

Dyslipidemia sales by country, 2004

Market analysis by drug class

Statins

Fibrates

Anti-dyslipidemics sales forecasts

Thrombosis

Introduction

Analysis of the top 10 anti-thrombotics

Market analysis by drug class

Heparins/ low molecular weight heparins

Anti-platelets

Vitamin K antagonists

v

Other anti-thrombotics

Anti-thrombotics sales forecasts

Cardiac therapies

Introduction

Analysis of the top 10 cardiac therapies

Market analysis by drug class

Nitrites/Nitrates

Anti-arrhythmics

Other cardiac therapy drugs

Chapter 4 Key players in the Eastern European cardiovascular market

Summary

Introduction

Eastern European market shares

Servier

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Sanofi-Aventis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Pfizer

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Novartis

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Krka

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Zentiva

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Gedeon Richter

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

vi

Merck & Co.

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts

Chapter 5 Appendix

IMS sales data

Glossary

Index

vii

List of Figures

Figure 1.1: Relationship between cardiovascular disease and risk factors

Figure 1.2: Risk factors associated with hypertension

Figure 1.3: Estimated prevalence of obesity in twelve Eastern European market, 2005 and 2010

Figure 2.4: External analysis of the Eastern European region

Figure 3.5: Competitive dynamics in the Eastern European cardiovascular market, 2003–04

Figure 3.6: Competitive dynamics in the global anti-hypertensives market by drug class, 2003–

Figure 3.7: Competitive dynamics of leading Eastern European anti-hypertensives by leading

brands, 2004

Figure 3.8: Competitive dynamics in the Eastern European anti-dyslipidemic market by drug class,

2003–04

Figure 3.9: Competitive dynamics of the top ten anti-dyslipidemic by drug class, 2004

Figure 3.10: Competitive dynamics in the Eastern European anti-thrombotic market by drug class,

2003–04

Figure 3.11: Competitive dynamics of the top ten anti-thrombotics in the Eastern European market

by drug class, 2004

Figure 3.12: Competitive dynamics in the Eastern European cardiac therapy market by drug class,

2003–04

Figure 3.13: Competitive dynamics of the top ten cardiac therapy by drug class, 2004

Figure 4.14: Market share of key players in the Eastern European cardiovascular market, 2000 and

2004

List of Tables

Table 1.1: Estimated prevalence of hypertension in twelve Eastern European markets, 2004

Table 1.2: Estimated prevalence of hypertension in twelve Eastern European markets, 2005–10

Table 1.3: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2004

Table 1.4: Estimated prevalence of dyslipidemia in twelve Eastern European markets, 2005–10

Table 1.5: Estimated prevalence of diabetes in twelve Eastern European markets, 2004

Table 1.6: Estimated prevalence of diabetes in twelve Eastern European markets, 2005–10

Table 1.7: Estimated prevalence of major cardiovascular diseases in the Eastern European

market, 2004

Table 1.8: Estimated incidence of ACS in the Eastern European market, 2004

Table 1.9: Estimated incidence of VTE in the Eastern European market, 2004

Table 1.10: Prevalence of stroke in twelve Eastern European markets, 2004

Table 2.11: Recent statistics on healthcare sector in twelve Eastern European markets, 2002

Table 2.12: Public and private financing in twelve Eastern European markets, 2002

Table 2.13: Sales of types of cardiovascular brands in the Eastern European pharmaceutical

market, 2000-04

Table 2.14: Sales of types of cardiovascular brands in twelve Eastern European markets, 2004

Table 3.15: Breakdown of Eastern European cardiovascular market by major therapeutic area,

2000–04

viii

Table 3.16: Top 10 cardiovascular products in the Eastern European market, 2004

Table 3.17: Cardiovascular sales across twelve Eastern European markets, 2004

Table 3.18: Breakdown of Eastern European anti-hypertensives market by drug class, 2000–04

Table 3.19: Competitive dynamics of the Eastern European anti-hypertensives market by leading

brands, 2004

Table 3.20: Market share of the leading classes of the anti-hypertensives in twelve Eastern

European markets, 2004

Table 3.21: Breakdown of the ACE inhibitor market in the Eastern European market by leading

brands, 2003–04

Table 3.22: Breakdown of the global CCB market by leading brands, 2003–04

Table 3.23: Breakdown of the Eastern European beta-blocker market by leading brands, 2003–

Table 3.24: Breakdown of the performance of drugs outside the major classes in the Eastern

European market by leading brands, 2003–04

Table 3.25: Sales forecasts for drug classes within the Eastern European anti-hypertensives

market, 2004–10

Table 3.26: Breakdown of the Eastern European anti-dyslipidemics market by drug class, 2000–

Table 3.27: Breakdown of Eastern European anti-dyslipidemic market by leading brands, 2004

Table 3.28: Anti-dyslipidemics market share in twelve Eastern European markets, 2004

Table 3.29: Sales forecasts for drug classes within the Eastern European anti-dyslipidemics

market, 2004–10

Table 3.30: Breakdown of Eastern European anti-thrombotic market by drug class, 2000–04

Table 3.31: Breakdown of Eastern European anti-thrombotic market by leading brands, 2004

Table 3.32: Sales forecasts for drug classes within the Eastern European anti-thrombotics market,

2004–10

Table 3.33: Breakdown of Eastern European cardiac therapy market by drug class, 2000–04

Table 3.34: Breakdown of the Eastern European cardiac therapy market by leading brands,

Table 4.35: Key players in the Eastern European cardiovascular market, 2000–2004

Table 4.36: Servier’s marketed cardiovascular portfolio, 2003-04

Table 4.37: Servier’s cardiovascular R&D pipeline, 2005

Table 4.38: Forecast sales for Servier’s cardiovascular portfolio, 2004–10

Table 4.39: Sanofi-Aventis’ marketed cardiovascular portfolio, 2003-04

Table 4.40: Sanofi-Aventis’ cardiovascular R&D pipeline, 2005

Table 4.41: Forecast sales for Sanofi-Aventis’ cardiovascular portfolio, 2004-10

Table 4.42: Pfizer’s marketed cardiovascular portfolio in Eastern European market, 2003-04

Table 4.43: Pfizer’s cardiovascular R&D pipeline, 2005

Table 4.44: Forecast sales for Pfizer’s Eastern European cardiovascular portfolio, 2004–10

Table 4.45: Novartis’ marketed cardiovascular portfolio, 2003-04

Table 4.46: Novartis’ cardiovascular R&D pipeline, 2005

Table 4.47: Forecast sales for Novartis’s cardiovascular portfolio, 2004–10

Table 4.48: Krka’s marketed cardiovascular portfolio, 2003-04

Table 4.49: Forecast sales for Krka’s cardiovascular portfolio, 2004–10

Table 4.50: Zentiva’s marketed cardiovascular portfolio, 2003-04

Table 4.51: Forecast sales for Zentiva’s cardiovascular portfolio, 2004–10

Table 4.52: Gedeon Richter’s marketed cardiovascular portfolio, 2003-04

Table 4.53: Forecast sales for Gedeon Richter’s cardiovascular portfolio, 2004–10

Table 4.54: Merck & Co’s marketed cardiovascular portfolio, 2003-04

Table 4.55: Merck & Co’s cardiovascular R&D pipeline, 2005

Table 4.56: Forecast sales for Merck & Co’s cardiovascular portfolio, 2004–10 143